Intravenous Nicotinamide Riboside Formulation for Low-Pain NAD+ Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing intravenous administration of NAD+ and its precursors, such as nicotinamide riboside (NR), often causes significant pain and inflammation, necessitating the development of a stable, aqueous-based formulation to minimize discomfort and enhance bioavailability.
Innovation Solution
A stable, crystalline powder form of NR or its derivatives is formulated in an aqueous-based intravenous (I.V.) composition, which can be reconstituted for administration, using sterilization processes like e-beam or gamma irradiation to maintain stability and minimize painful side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If NAD+ or its precursors are administered intravenously, then cellular NAD+ levels are enhanced, but significant pain and inflammation occur
Solution Approach 1:
The patent changes the chemical form of the NAD+ precursor from conventional forms (nicotinamide, nicotinic acid) to nicotinamide riboside, which has different pharmacokinetic properties. This parameter change in molecular structure allows for enhanced cellular uptake and conversion to NAD+ while reducing the harmful inflammatory and painful side effects associated with conventional forms during intravenous administration
Solution Approach 2:
The patent uses nicotinamide riboside as an intermediary compound that serves as a precursor to NAD+. This intermediary approach allows the body to convert the administered compound into the desired NAD+ form through natural metabolic pathways, thereby achieving the therapeutic effect of elevated NAD+ levels while avoiding the direct harmful effects of administering NAD+ or conventional precursors intravenously
2Quantity of substance
If conventional NAD+ formulations are used, then NAD+ supplementation is achieved, but stability and bioavailability are insufficient
Solution Approach 1:
The patent employs parameter changes by selecting nicotinamide riboside as the precursor compound, which possesses superior chemical stability in aqueous formulations compared to conventional NAD+ forms. This molecular parameter change enables the development of stable, sterile, aqueous-based intravenous formulations that maintain their composition integrity while providing enhanced bioavailability and efficient cellular conversion to NAD+
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively enhances NAD+ levels in cells with minimal pain and discomfort, reducing inflammation markers and improving recovery time, cognitive function, and overall comfort during administration.
Implementation Method 1
using sterilization processes like e-beam or gamma irradiation to maintain stability
Implementation Method 2
using sterilization processes like e-beam or gamma irradiation to maintain stability
Data Source
AI summary
A stable intravenous (I.V.) composition includes nicotinamide riboside (NR) as described, or other nicotinyl riboside compounds which are NAD+ precursors, in said intravenous form. NR chloride may be provided in an intravenous (I.V.) formulation for administration to a human subject.